Clinical and therapeutic perspectives of gene expression profiling for breast cancer

Annals of Oncology

Volumn 18, Issue SUPPL. 6, 2007, Pages

  Chiuri, V E ^a   Leo, G ^a   Lorusso, V ^a  

^a VITO FAZZI HOSPITAL   (Italy)

Author keywords

Breast cancer; Gene expression profiling; Predictive; Prognostic

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; HORMONE RECEPTOR; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 17B RECEPTOR; TAMOXIFEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HOXB13; UNCLASSIFIED DRUG;

BREAST CANCER; BREAST SURGERY; CANCER CLASSIFICATION; CANCER GRADING; CANCER HORMONE THERAPY; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG RESPONSE; GENE EXPRESSION PROFILING; GENOME ANALYSIS; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MICROARRAY ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; BREAST TUMOR; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PREDICTION AND FORECASTING; REVIEW;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PREDICTIVE VALUE OF TESTS;

EID: 35748937074     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm226     Document Type: Conference Paper

References (41)

1. Schwartsmann G, Ratain MJ, Cragg GM et al. Anticancer drug discovery development throughout the world. J Clin Oncol 2002; 20: 47S-59S.
2. Winer E, Morrow M, Osborne C et al. Malignant tumors of the breast. In V, Hellman S, Rosenberg S (eds): Cancer. Principles & Practice of Oncology. Philadelphia, PA: Lippincot Williams & Wilkins 2001; 1651-1726.
3. Goldhirsch A, Wood WC, Gelber RD et al. Meeting highlights: Updated international expert consensus on the primary therapy for early breast J Clin Oncol 2003; 21: 3357-3365.
4. Marty M, Cognetti F, Maraninchi D et al. Efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: Results of a randomized phase II trial by the M77001 study group. J Clin Oncol 2005; 23: 4265-4274.
5. D'Eredita G, Giardina C, Martellotta M et al. Prognostic factors in breast cancer: The predictive value of Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution. Eur J Cancer 2001; 37: 591-596.
6. Olivotto IA, Bajdik CD, Ravdin PM et al. Population-based validation of prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005; 23: 2716-2725.
7. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast Nature 2000; 406: 747-752.
8. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
9. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423.
10. Chang JC, Hilsenbeck SG, Fuqua SA. Genomic approaches in the management and treatment of breast cancer. Br J Cancer 2005; 92: 618-624.
11. van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
12. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
13. Buyse M, Sherene L, van't Veer LJ et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006; 98: 1183-1192. Online Protocol in www.mindact.org Web site
14. Paik S, Shak S, Thang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826.
15. Habel LA, Shak S, Jacobs MK et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006; 8: R25.
16. Wang Y, Klijng JG, Zhang Y et al. Gene expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365: 671-679.
17. Chang HY, Sneddon JB, Alizadeh AA et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PloS Biol 2004; 2: E7.
18. Chang HY, Nuyten DS, Sneddon JB et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005; 102: 3738-3743.
19. Chi JT, Wang Z, Nuyten DS et al. Gene expression programs in response to hypoxia: Cell type specificity and prognostic significance in human cancers. Plos Med 2006; 3: E47.
20. Nuyten DS, Kreike B, Hart AA et al. Predicting local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 2006; 8: R62.
21. Tsumagari K, Chijiiwa K, Hisaki N et al. Postoperative prognosis of node-negative breast cancers predicted by gene-expression profiling on a cDNA microarray of 25,344 genes. Breast Cancer 2005; 12: 166-177.
22. Sotiriou C, Wirapati P, Loi S et al. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98: 262-272.
23. Liu R, Wang X, Chen GY et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007; 356: 217-226.
24. Fan C, Oh DS, Wessels L et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006; 355: 560-569.
25. Jansen MP, Foekens A van Staveren IL et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 2005; 23: 732-740.
26. Ma XJ, Wang Z, Ryan PD et al. A two-gene expression rafio predicts clinical outcome in breast cancer patents treated with tamoxifen. Cancer Cell 2004; 5: 607-616.
27. Inoue A, Yoshida N, Omoto Y et al. Development of cDNA microarray for expression profiling of estrogen-responsive genes. J Mol Endocrinol 2002; 29: 175-192.
28. Saji S, Hayashi S, Yoshida N et al. Therapeutic utility of histone deacetylase 6 regulation via estrogen signaling in human breast cancer MCF-7. Oncogene 2005; 24: 4531-4539.
29. Zhang Z, Yamashita H, Toyama T et al. HDAC6 expression is correlated with better prognosis in breast cancer. Clin Cancer Res 2004; 10: 6962-6968.
30. Hayashi S, Yamaguchi Y. Basic research for hormone-sensitivity of breast cancer. Breast Cancer 2006; 13: 123-128.
31. Hayashi S, Yamaguchi Y. Estrogen signaling and prediction of endocrine therapy. Cancer Chemother Pharmacol 2005; 56 (Suppl 1): 27-31.
32. Folgueira MA, Carraro DM, Brentani H et al. Gene expression associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 2005; 11: 7434-7443.
33. Modlich O, Prisack HB, Munnes M et al. Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: Translation of microarray data into clinically useful predictve signatures. J Transl Med 2005; 3: 32.
34. Chang JC, Wooten EC, Tsimelzon A et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 2005; 23: 1169-1177.
35. Iwao-Koizumi K, Matoba R, Ueno N et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005; 23: 422-431.
36. Yoshimoto M, Makita M, Nishimura S et al. Prediction of the therapeutic response to paclitaxel by gene expression profiling in neoadjuvant chemotherapy for breast cancer. 40th Annual ASCO Meetng Proceeding. J Clin Oncol 2004; 22: 14S (Abstr 500).
37. Gianni L, Zambetti M, Clark K et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005; 23: 7265-7277.
38. Hess KR, Anderson K, Symmans WF et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006; 24: 4236-4244.
39. Ayers M, Symmans WF, Stec J et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004; 22: 2284-2293.
40. Pusztai L, Hess KR, Anderson K et al. Pharmacogenomic predictor of complete response to preoperative paclitaxel and 5-fluorouracil, doxorubicin, cyclophosphamide chemotherapy in breast cancer. 42nd Annual ASCO Meeting Proceeding. J Clin Oncol 2006; 24: 18S (Abstr 10000).
41. Simon R, Radmacher MD, Dobbin K et al. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 2003; 95: 14-18.